The use of immunotherapy to treat Triple Negative Breast Cancer
DOI:
https://doi.org/10.58445/rars.1242Keywords:
Immunotherapy, cancer, Triple Negative Breast CancerAbstract
This research paper dives into all aspects of TNBC, which include biological components, treatment options, and future outlooks for TNBC. This research and knowledge was done through the help of my Polygence mentor, and through the use of clinical trials as well as other informative sites. Majority of this research paper covers what defines and makes up TNBC, and how it is different from other cancers, as well as specific trials which focus on the treatment aspect of TNBC meanwhile noting the difficulty of treating TNBC due to the lack of receptors possesed in the cancer. Over all this paper is meant to inform individuals about all aspects of breast cancer while being unbiased and informative.
References
Delves, P. J. (2020). Innate and adaptive systems of immunity. In The Autoimmune Diseases (pp. 45-61). Academic Press.
Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018 Apr 19;9(10):1773-1781. doi: 10.7150/jca.24577. PMID: 29805703; PMCID: PMC5968765.
Lee, S. H., Kim, Y. S., Han, W., Ryu, H. S., Chang, J. M., Cho, N., & Moon, W. K. (2016). Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine, 95(37), e4874. https://doi.org/10.1097/MD.0000000000004874
Soare, G. R., & Soare, C. A. (2019). Immunotherapy for Breast Cancer: First FDA Approved Regimen. Discoveries (Craiova, Romania), 7(1), e91. https://doi.org/10.15190/d.2019.4
Dong, Y., Sun, Q., & Zhang, X. (2017). PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 8(2), 2171–2186. https://doi.org/10.18632/oncotarget.13895
NCT05949021
NCT05633654
Chue, B. M., & La Course, B. D. (2019). Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years). Medicine, 98(38), e17251. https://doi.org/10.1097/MD.0000000000017251
Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The major histocompatibility complex and its functions. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27156/
Jacobs, F., Agostinetto, E., Miggiano, C., De Sanctis, R., Zambelli, A., & Santoro, A. (2023). Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. Cancers, 15(11), 2933. https://doi.org/10.3390/cancers15112933
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15(7), 1796. https://doi.org/10.3390/pharmaceutics15071796
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023). Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Frontiers in Immunology, 14, 1153990.
Bai, X., Zhou, Y., Yokota, Y., Matsumoto, Y., Zhai, B., Maarouf, N., ... & Wands, J. R. (2022). Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Journal of Experimental & Clinical Cancer Research, 41(1), 132
Amirikia, K. C., Mills, P., Bush, J., & Newman, L. A. (2011). Higher population‐based incidence rates of triple‐negative breast cancer among young African‐American women: implications for breast cancer screening recommendations. Cancer, 117(12), 2747-2753.
Hsu, J. Y., Chang, C. J., & Cheng, J. S. (2022). Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Scientific Reports, 12(1), 729.
Tiscoski, K. A., Giacomazzi, J., Rocha, M. S., Gössling, G., & Werutsky, G. (2023). Real-world data on triple-negative breast cancer in Latin America and the Caribbean. ecancermedicalscience, 17. 1- Katz, H., & Alsharedi, M. (2018). Immunotherapy in triple-negative breast cancer. Medical oncology, 35, 1-9.
Seligson JM, Patron AM, Berger MJ, Harvey RD, Seligson ND. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Annals of Pharmacotherapy. 2021;55(7):921-931. doi:10.1177/1060028020966548
https://www.breastcancer.org/treatment/targeted-therapy/trodelvy
Gunturi, A., & McDermott, D. F. (2015). Nivolumab for the treatment of cancer. Expert opinion on investigational drugs, 24(2), 253-260.
Downloads
Posted
Categories
License
Copyright (c) 2024 Boglarka Sinka
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.